Tenax Therapeutics, Inc. (TENX)
- Previous Close
3.5500 - Open
3.4400 - Bid --
- Ask --
- Day's Range
3.4400 - 3.6151 - 52 Week Range
3.4400 - 61.2000 - Volume
52,677 - Avg. Volume
108,227 - Market Cap (intraday)
6.795M - Beta (5Y Monthly) 2.24
- PE Ratio (TTM)
-- - EPS (TTM)
-31.0400 - Earnings Date May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
32.50
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
www.tenaxthera.comRecent News: TENX
Performance Overview: TENX
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TENX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TENX
Valuation Measures
Market Cap
6.95M
Enterprise Value
-2.34M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.86
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-68.21%
Return on Equity (ttm)
-160.79%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-7.71M
Diluted EPS (ttm)
-31.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
9.79M
Total Debt/Equity (mrq)
6.19%
Levered Free Cash Flow (ttm)
-3.79M
Research Analysis: TENX
Company Insights: TENX
TENX does not have Company Insights